loading
Kiora Pharmaceuticals Inc stock is traded at $3.67, with a volume of 11,872. It is down -0.68% in the last 24 hours and up +5.64% over the past month. Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$3.675
Open:
$3.73
24h Volume:
11,872
Relative Volume:
0.38
Market Cap:
$10.46M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.3984
EPS:
-9.2108
Net Cash Flow:
$7.14M
1W Performance:
-5.19%
1M Performance:
+5.64%
6M Performance:
-20.99%
1Y Performance:
-34.60%
1-Day Range:
Value
$3.5201
$3.75
1-Week Range:
Value
$3.46
$3.85
52-Week Range:
Value
$3.00
$8.982

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Name
Name
Kiora Pharmaceuticals Inc
Name
Phone
781-788-8869
Name
Address
332 ENCINITAS BOULEVARD, ENCINITAS
Name
Employee
12
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
KPRX's Discussions on Twitter

Kiora Pharmaceuticals Inc Stock (KPRX) Latest News

pulisher
Oct 30, 2024

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 29, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance

Oct 29, 2024
pulisher
Sep 25, 2024

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN

Sep 25, 2024
pulisher
Sep 12, 2024

Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com

Sep 12, 2024
pulisher
Aug 23, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World

Aug 23, 2024
pulisher
Aug 20, 2024

Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia

Aug 20, 2024
pulisher
Aug 20, 2024

Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India

Aug 20, 2024
pulisher
Aug 17, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World

Aug 17, 2024
pulisher
Aug 13, 2024

How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union

Aug 13, 2024
pulisher
Aug 09, 2024

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance

Aug 09, 2024
pulisher
Aug 06, 2024

KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Aug 06, 2024
pulisher
Jul 30, 2024

Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe

Jul 30, 2024
pulisher
Jul 30, 2024

Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada

Jul 30, 2024
pulisher
Jul 30, 2024

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile

Jul 30, 2024
pulisher
Jul 24, 2024

HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World

Jul 24, 2024
pulisher
Jul 24, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World

Jul 24, 2024
pulisher
Jul 18, 2024

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World

Jul 18, 2024
pulisher
Jul 11, 2024

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow

Jul 11, 2024
pulisher
Jul 10, 2024

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan

Jul 10, 2024
pulisher
Jul 10, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World

Jul 10, 2024
pulisher
Jul 05, 2024

EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow

Jul 05, 2024
pulisher
Jul 01, 2024

Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com

Jul 01, 2024
pulisher
Jul 01, 2024

Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia

Jul 01, 2024
pulisher
Jul 01, 2024

Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada

Jul 01, 2024
pulisher
Jul 01, 2024

Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks

Jul 01, 2024
pulisher
Jul 01, 2024

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com

Jul 01, 2024
pulisher
Jun 25, 2024

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile

Jun 25, 2024
pulisher
Jun 25, 2024

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan

Jun 25, 2024
pulisher
Jun 24, 2024

CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK

Jun 24, 2024
pulisher
Jun 21, 2024

Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com

Jun 21, 2024
pulisher
Jun 20, 2024

KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView

Jun 20, 2024
pulisher
Jun 19, 2024

Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow

Jun 19, 2024
pulisher
Jun 19, 2024

Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow

Jun 19, 2024
pulisher
Jun 18, 2024

Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance

Jun 18, 2024
pulisher
Jun 15, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Upgraded to Strong-Buy at Maxim Group - Defense World

Jun 15, 2024
pulisher
Jun 15, 2024

Brian M. Strem Buys 3000 Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Stock - Defense World

Jun 15, 2024
pulisher
Jun 15, 2024

NorthWest Healthcare Properties Real Estate Investment Trust (TSE:NWH) Declares Monthly Dividend of $0.03 - Defense World

Jun 15, 2024
pulisher
Jun 15, 2024

Kiora Pharmaceuticals EVP finance buys shares worth $525Investing.com ZA - Investing.com South Africa

Jun 15, 2024
pulisher
Jun 15, 2024

Erin Parsons Purchases 5260 Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Stock - Defense World

Jun 15, 2024
pulisher
Jun 15, 2024

Kiora Pharmaceuticals exec buys $7.6k in company stock - Investing.com India

Jun 15, 2024
pulisher
Jun 14, 2024

Kiora Pharmaceuticals EVP finance buys shares worth $525 By Investing.com - Investing.com

Jun 14, 2024
pulisher
Jun 14, 2024

Kiora Pharmaceuticals exec buys $7.6k in company stock By Investing.com - Investing.com Australia

Jun 14, 2024
pulisher
Jun 14, 2024

Kiora Pharmaceuticals CEO acquires $14.9k in company stock By Investing.com - Investing.com Australia

Jun 14, 2024

Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):